<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FA6918F5-984C-46E4-88C2-CE8FB83A71B5"><gtr:id>FA6918F5-984C-46E4-88C2-CE8FB83A71B5</gtr:id><gtr:firstName>Bruce</gtr:firstName><gtr:surname>Ponder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/45391D67-BD2D-4652-9A39-AA639FCA69EB"><gtr:id>45391D67-BD2D-4652-9A39-AA639FCA69EB</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D689BE86-A21C-409A-B98D-39C5C29F7C30"><gtr:id>D689BE86-A21C-409A-B98D-39C5C29F7C30</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Ledermann</gtr:surname><gtr:orcidId>0000-0003-3799-3539</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0DD47AE4-BCAA-48E1-8B13-3F2428BDDA18"><gtr:id>0DD47AE4-BCAA-48E1-8B13-3F2428BDDA18</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>L.</gtr:otherNames><gtr:surname>Harris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ACE617BE-3E38-4485-9965-C2A062A22E3A"><gtr:id>ACE617BE-3E38-4485-9965-C2A062A22E3A</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Gibbons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/070D06BC-BBE4-4704-B8FF-A8584A060B13"><gtr:id>070D06BC-BBE4-4704-B8FF-A8584A060B13</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Derek</gtr:otherNames><gtr:surname>Brenton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C884A527-A140-4623-BCF3-E307CFEAD8B5"><gtr:id>C884A527-A140-4623-BCF3-E307CFEAD8B5</gtr:id><gtr:firstName>Carlos</gtr:firstName><gtr:surname>Caldas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8D08276C-60D4-4758-A896-576D2092C30D"><gtr:id>8D08276C-60D4-4758-A896-576D2092C30D</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E68F56EC-6BDB-4B33-AA69-B9F7AB082572"><gtr:id>E68F56EC-6BDB-4B33-AA69-B9F7AB082572</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8800C806-3FC3-4159-8021-F5A5F63ECF23"><gtr:id>8800C806-3FC3-4159-8021-F5A5F63ECF23</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Begent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9FD8D16F-0F0B-47CA-A4C1-F8C2B762A747"><gtr:id>9FD8D16F-0F0B-47CA-A4C1-F8C2B762A747</gtr:id><gtr:firstName>Marta</gtr:firstName><gtr:otherNames>Zofia</gtr:otherNames><gtr:surname>Kwiatkowska</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16DE0E89-C57F-4E33-91C0-DC4B3CCCDB64"><gtr:id>16DE0E89-C57F-4E33-91C0-DC4B3CCCDB64</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D1AF878A-0BD5-44E6-AAC7-E45DD6010A00"><gtr:id>D1AF878A-0BD5-44E6-AAC7-E45DD6010A00</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB4204F3-D021-48C8-89A2-50B4A32201FD"><gtr:id>DB4204F3-D021-48C8-89A2-50B4A32201FD</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>G.</gtr:otherNames><gtr:surname>Johnston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/94F9A3A6-BB58-4D9C-A7D0-5FBAECFB8541"><gtr:id>94F9A3A6-BB58-4D9C-A7D0-5FBAECFB8541</gtr:id><gtr:firstName>Sylvia</gtr:firstName><gtr:surname>Nagl</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C1917109-0148-4573-A9BF-29A28B75A93C"><gtr:id>C1917109-0148-4573-A9BF-29A28B75A93C</gtr:id><gtr:firstName>Ron</gtr:firstName><gtr:surname>Perrott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300648"><gtr:id>6017C012-6F84-4196-B656-F0B72FC2B834</gtr:id><gtr:title>CancerGRID-Final Application</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300648</gtr:grantReference><gtr:abstractText>CancerGRID will contribute to activities such as open days to engage the public in cancer research. CancerGRID will also aim at engaging patient representatives and will closely integrate with activities from the NHS that impinge on cancer care delivery.</gtr:abstractText><gtr:technicalSummary>CancerGRID is a consortium to develop open standards for clinical cancer informatics. The Consortium will concentrate on breast cancer translational clinical trials, but since all informatics tools will be developed using open source, open access, open development and a federated structure it is anticipated that solutions will be portable to other clinical scenarios. The Goal of our application is to use a modular approach to provide solutions for ?simple? problems using grid-based informatics: 1-Developing a template for e-clinical trials using a translational clinical trial already ongoing as a pilot (NeoTANGO); 2-Linking existing clinical trial data with molecular profiling information obtained from paraffin-embedded tumour samples; 3- Linking genetic epidemiology data with molecular pathology and clinical outcome data; ; and 4-Using GRID-based collaborative tools to run clinical trials. The Consortium will develop: i) template forms, vocabularies, common data elements and biomedical objects for prospective running of multicentric translational clinical trials using the grid; ii) vocabularies, common data elements and biomedical objects for retrospective analysis of phase III clinical trials with integrated molecular analysis of paraffin-embedded samples and integration with cancer registry; iii) tools to link genetic epidemiology data, with molecular pathology, clinical trials and cancer outcome data using ABC as a demonstrator project; iv) a telemedicine infrastructure for running and managing translational clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2009-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2304949</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine (UCSF)</gtr:department><gtr:description>OCRe</gtr:description><gtr:id>72D33B7E-1AC3-4984-8618-C23B08A2F218</gtr:id><gtr:impact>The published ontology is available from Bioportal: http://bioportal.bioontology.org/ontologies/39291</gtr:impact><gtr:outcomeId>sfCkSCwp6P1-1</gtr:outcomeId><gtr:partnerContribution>Expertise in ontology creation</gtr:partnerContribution><gtr:piContribution>Members of our research team initiated the ontology development and acted as ontology editor in collaboration with Stanford, UCSF and Manchester University. Contribution to the ontology content in OWL using Prot&amp;eacute;g&amp;eacute;. Co-authored a web-based publication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BCAC</gtr:description><gtr:id>51F59859-A972-48CC-8EFB-E1DEC584F4D2</gtr:id><gtr:impact>Collected tissue microarray data from 10 different international centres in the Breast Cancer Association Consortium (BCAC). The data collected has been analysed and a manuscript is in preparation to describe the results.</gtr:impact><gtr:outcomeId>WW9Ge3VseE9-1</gtr:outcomeId><gtr:partnerContribution>Providing a user group for the Tissue Microarray Image Scoring Application, enabling testing and use of the software by multiple international partners in the Breast Cancer International Consortium (BCAC).</gtr:partnerContribution><gtr:piContribution>Software engineering expertise. Providing the Tissue Microarray Image Scoring application (see Research Materials) to enable multi-site scoring of images. Providing a processing pipeline to track tissue sample identifiers to enable scoring data to be linked back to clinical data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Astronomy</gtr:department><gtr:description>Pathgrid</gtr:description><gtr:id>BD332235-A38F-4CDD-99CA-68674372C528</gtr:id><gtr:impact>The collaboration led to a publication in 2010 (Pubmed ID: 20643686). The collaboration is multi-disciplinary involving Astronomers, Oncologists, Pathologists, Image Analysis experts, software developers and statisticians. A second manuscript is in preparation which describes the results of applying image analysis algorithms developed through this collaboration for analysing thousands of breast cancer tissue microrray images.</gtr:impact><gtr:outcomeId>oWarfhb6Y2s-1</gtr:outcomeId><gtr:partnerContribution>Collaborators at the Insititute of Astronomy have provided expertise in image analysis algorthims. Discussions between Cancergrid software developers, image analysis experts, pathologists and clinicians have led to the development of an analysis pipeline, incorporating metadata describing tissue images and adapting astronomical workflows and image analysis algorthims developed for the AstroGrid project for the high-throughput analysis of tissue microarray images.</gtr:partnerContribution><gtr:piContribution>Cancergrid staff from both the University fo Cambridge and University of Oxford have taken part in discussions to drive the implementation of this software. Cancergrid staff at Cambridge have been responsible from provision of images and metadata for image analysis. Cancergrid staff have been responsible for deployment of the software at the Cambridge Research Institute, and long-term planning for provision of appropriate databases to store the results of image analysis for downstream statistical analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Informatics Inititive</gtr:department><gtr:description>NCRI Informatics</gtr:description><gtr:id>F9F9ADC0-0294-4176-9F48-F6D50DF220AD</gtr:id><gtr:impact>Active discussions throughout the Cancergrid project and attendence at NCRI and caBIG joint conferences enabled Cancergrid to adapt and tailor our software development efforts to the needs of the scientific and medical communities, whilst keeping abreast of complimentary efforts to develop and use data standards in the cancer field. Our efforts were rewarded in several poster awards at the NCRI-caBIG joint conference in 2008 (see Awards and Recognition section).</gtr:impact><gtr:outcomeId>i8qQnL1o6UC-1</gtr:outcomeId><gtr:partnerContribution>The NCRI Informatics Initiative together with caBIG have organised annual joint conferences which have been an excellent forum for collaboration between ourselves and international efforts on data sharing.</gtr:partnerContribution><gtr:piContribution>Brought Cancergrid expertise to the NCRI efforts in data sharing. Several of the Cancergrid investigators were members of the NCRI Informatics Task Force, which provides a forum for consultation with the scientific, medical and informatics communities.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute (NCI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>caBIG</gtr:description><gtr:id>9E388D9F-4369-48E7-8361-3CBB2D514EEC</gtr:id><gtr:impact>Delivered a presentation on evolving health informatics at Microsoft eScience workshop in 2008. Paper published for data standards in antibody experiments (PMID: 19224941).</gtr:impact><gtr:outcomeId>YU9CuB6pdJ5-1</gtr:outcomeId><gtr:partnerContribution>Expertise on caDSR to enable integration of the US NCI metadata elements with those used in the the UK Cancergrid project. Provision of NCI Common Data Element browser.</gtr:partnerContribution><gtr:piContribution>Software engineering expertise, providing a light-weight metadata repository and other software tools (see Research Materials - Cancergrid Metadata Registry and Query Service Manager Plugins). Providing Common Data Element defintions for breast cancer clinical trials and minimum information collection for antibody experiments.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>eHealth</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>14E9E8DC-B0AA-48E4-9B02-EC5F7C7701F4</gtr:id><gtr:impact>Participation in technical and specification work for record design in the NHS, representing interests of clinical researchers in the approach and design of medical records in England

Participation remains ongoing - developing opportunities to provide cancergrid tools to record designers</gtr:impact><gtr:outcomeId>rbKgdTWT5ZL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NATO</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>5565BD61-6B8D-4044-84B4-3662CE28F17B</gtr:id><gtr:impact>The interoperability taskforce within NATO is adopting the CancerGrid tools for prototyping purposes, linking data definitions and promoting data standards across different partners in the organisation. A wider deployment is being considered.

The existing &amp;quot;metadata repository&amp;quot; used by the NATO taskforce is likely to be withdrawn, and replaced by a more sophisticated solution based on UK CancerGrid/ US NCI approaches.</gtr:impact><gtr:outcomeId>PJwKAisWmn3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>eGovernment</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>90136375-A661-489C-B200-4A370131C56C</gtr:id><gtr:impact>Development of guidelines and recommendations for the development of government interoperability initiatives related to both open government and internal government efficiency

Continued ongoing contact with civil servants</gtr:impact><gtr:outcomeId>kLDQ8nZEKet</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI Informatics Task Force</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>F2C7C545-B0A4-4568-A228-0C86DF1E15EB</gtr:id><gtr:impact>The NCRI Informatics Initiative has taken a more data- and semantics-driven approach to data sharing and to facilitating communication and collaboration across the UK community.

The results of this work will be informing part of the new Stratified Medicines Initiative.</gtr:impact><gtr:outcomeId>TPareB3C9Qp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientifique Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>54B502C3-34D0-4186-AE21-7AE40EC1D80E</gtr:id><gtr:impact>The talk provoked discussion about the impact of translational research and the potential benefits for society as a whole.

Important dissemination activity in informing members of the public how clinical evidence is collected and the potential benefits of clinical trials to society as a whole.</gtr:impact><gtr:outcomeId>LRgpZutWGMz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gates Foundation visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>2CF21B3B-8232-4D20-9176-B06637C95D43</gtr:id><gtr:impact>Bill Gates visited Oxford and spent 30 minutes - in a small meeting - discussing the software and the approach to clinical trials management with two of the CancerGrid investigators. He asked that they should visit Microsoft once more to meet with the metadata experts leading Office development.

The subsequent meeting in Redmond led to a proposal for deployment, and to new channels for providing input into product development at Microsoft, as well as into open source bioinformatics tools (such as Microsoft's new &amp;quot;Microsoft Biology Foundation&amp;quot;).</gtr:impact><gtr:outcomeId>NFHZDwCqsKs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>108741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Extending Pathgrid miniPIPSS</gtr:description><gtr:fundingOrg>Science and Technologies Facilities Council (STFC)</gtr:fundingOrg><gtr:id>1621CA9D-6BC4-4396-A2B0-48A04B997300</gtr:id><gtr:outcomeId>ewyZt2jXUoX0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92304</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Discipline Hopping Awards - Exploiting Astrogrid / Cancergrid systems</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6A865614-3E7E-410C-A144-65567A7FDC84</gtr:id><gtr:outcomeId>PSBxFVxmaPW0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14624435</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovative Technologies for Stratified and Experimental Medicine, Co-I (PI: Patrick Maxwell, other Co-Is: Fiona Gilbert, Kevin Brindle, Stephen O'Rahilly, Edward Bullmore, James Brenton)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A32EB528-AB8C-47D5-9EE5-16F7037584F4</gtr:id><gtr:outcomeId>56d961698bb1b6.54699815</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Grid, Cloud, and Web-based services, tools, and databases for the efficient annotation and generation of forms and other artifacts for the acquisition and processing of clinical research information.</gtr:description><gtr:grantRef>G0300648</gtr:grantRef><gtr:id>160EAFEC-F3A0-4470-AD51-64DAC679C4C3</gtr:id><gtr:impact>This technology has been used to run clinical studies - e.g. for pneumoccal vaccines in Nepal - and as a platform for future semantic interoperability in organisations such as the Scottish Government, NATO, and the MRC's own Data Support Service.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>XYuKkFwv4vW</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Metadata Services and Tools for Semantic Interoperability</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This server-side application enables the conversion of images from an image store into deep-zoom images which can be presented by the Image Scorer application.</gtr:description><gtr:id>543ED287-CEE3-47BE-A57F-F0C774005262</gtr:id><gtr:impact>This has enabled patholgists to view images on-screen, enabling the user to zoom and pan around images, mimicing the experience of viewing images with a microscope.</gtr:impact><gtr:outcomeId>BWPHXgHPT6r</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Deep Zoom Image Converter</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Plugins and addins for Enterprise Architect, Microsoft Excel 2007 and Microsoft InfoPath 2007. These plugins enable the communication of metadata to and from the CancerGrid Metadata Registry.</gtr:description><gtr:id>814ABD68-4C7B-4A28-9D1D-1225AC235AB1</gtr:id><gtr:impact>The plugins are the foundation of the National Bone Marrow Donor Program collaboration in which spreadsheets that describe form variables are annotated using these plugins against the metadata registry component</gtr:impact><gtr:outcomeId>mR4bxWYUofE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Query Service Manager Plugins</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The SQIV toolset allows for the processing of data marked up with meta-data into RDF. That a toolkit has been used for clinical data transformation and integration.</gtr:description><gtr:id>0371B7E6-81AC-4358-80C6-1CB6188BBAEE</gtr:id><gtr:impact>This toolkit has been utilised to support the retrospective analysis of data collected to different standards, drawn from five centres in the Anglo-Canadian METABRIC project. The use of the tool for the management and integration of this data was described in BMC Medical Genomics 2009, 2:66.</gtr:impact><gtr:outcomeId>ZotdfgnFvqi</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>SQIV</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An ISO11179-compliant metadata registry</gtr:description><gtr:id>CA5FE62E-664F-4628-9EBF-47EB6E944640</gtr:id><gtr:impact>The metadata registry is the central component of the MRC Data Support Service gateway (project in progress) providing variable level documentation for important MRC population studies to support data sharing an reuse activities.

The metadata registry is also in use by the US National Blood Marrow Donor Program to rationalise and document variables from their clinical and laboratory forms so that they may become caBIG compliant. The registry has been taken on by Ohio State University (openMDR) for wider use in clinical research outside the cancer arena in the US.

The METABRIC project has utilised this tool to standardise and integrate clinical data from five different data sources for meta-analysis. This work was published and is described in the publication section. It has also been used to support for standardisation of tissue microarray (TMA) at the CRUK-Cambridge Research Institute and collaborating institutions, such as Strangeways Research Laboratory, University of Cambridge. This standardisation of data has facilitated the high-throughput flow of tissue data between the collaborating laboratories. It has been adopted for use within the US caBIG initiative, and is being evaluated by a number of organisations within the UK and around the world including Sage Bionetworks, MD Anderson Cancer Clinic, and the Scottish Government.</gtr:impact><gtr:outcomeId>fXvqxwUmCFg</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cancergrid Metadata Registry</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A tool that enables high-throughput scoring of tissue microarray images via the internet.</gtr:description><gtr:id>6A160361-26A1-4663-8926-69ADAA41E87A</gtr:id><gtr:impact>Has enabled multi-site scoring of tissue microarray images. For example in the international Breast Cancer Consortium it was used by pathologists based at Addenbrookes in Cambridge and the National Insititute of Health in Washington for the viewing and scoring of images to enable validation of automated scoring methods being developed at CRUK Cambridge Research Institute. We plan to make the tool available to pathologists at additional sites to further collaboration and increase the throughput of data collection in these multi-site studies. An abstract was submitted at the Breakthrough Breast Cancer conference 2011, which described the analysis of data collected using this tool in the Breast Cancer Association Consortium (BCAC). We have made the source code available at sourceforge (http://sourceforge.net/projects/cancergrid-tma/) to encourage further development and use by other groups. Our manuscript describing the functionality and use of this tool is currently under review at BMC Bioinformatics.</gtr:impact><gtr:outcomeId>GxYtAtJtowg</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tissue Microarray Image Scorer</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://sourceforge.net/projects/cancergrid-tma/</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>13C3418B-6767-4159-892C-0F0EAA7BEC32</gtr:id><gtr:title>A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a799480261950.63875468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA2D177B-8662-4F71-93D3-94D8CBA92C96</gtr:id><gtr:title>Imaging biomarker roadmap for cancer studies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>5899d4b5b122f6.58372838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>298DE411-3C23-4E24-99D6-85AC8CBACF88</gtr:id><gtr:title>Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00f2477827731fcbe737158a172bb54f"><gtr:id>00f2477827731fcbe737158a172bb54f</gtr:id><gtr:otherNames>Andreis D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn><gtr:outcomeId>5a79b21adc6be7.83479877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B2E114D-E66B-47B9-A40D-A5F137DAD7C8</gtr:id><gtr:title>Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage.</gtr:title><gtr:parentPublicationTitle>Anticancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fef59d988632d50bfcfa6b4d556481f"><gtr:id>1fef59d988632d50bfcfa6b4d556481f</gtr:id><gtr:otherNames>Koukourakis MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0250-7005</gtr:issn><gtr:outcomeId>5a7995aa0dee68.09912311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB6B151B-1447-45FA-917E-B36CBC05D474</gtr:id><gtr:title>Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed79aee5bbc06845ed5fa0d99b9b1afc"><gtr:id>ed79aee5bbc06845ed5fa0d99b9b1afc</gtr:id><gtr:otherNames>Goberdhan DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>5899d4b24b1de5.36587771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEBA9D30-AC45-4FC0-906E-7F324159058B</gtr:id><gtr:title>Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0dc957f193284ffded40111bff3db5b"><gtr:id>c0dc957f193284ffded40111bff3db5b</gtr:id><gtr:otherNames>Ali HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>545362c8e161c2.00161847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13A16AAB-0A3C-45A6-A705-88A3ABBFC55A</gtr:id><gtr:title>Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments.</gtr:title><gtr:parentPublicationTitle>Cancer &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40921e61f7b71eb633519b3ff4ba3425"><gtr:id>40921e61f7b71eb633519b3ff4ba3425</gtr:id><gtr:otherNames>Peck B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2049-3002</gtr:issn><gtr:outcomeId>57988f47ce35b7.75731447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C30315D3-1C49-40CF-BB67-D5C1501FBE0B</gtr:id><gtr:title>Advances in Hypoxia-Inducible Factor Biology.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eb82a334010a9abe7be02483e62e969"><gtr:id>7eb82a334010a9abe7be02483e62e969</gtr:id><gtr:otherNames>Choudhry H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>5a79947c718ea2.05817921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32A7C0EE-AD3A-4F6C-8529-2FDE04D406EB</gtr:id><gtr:title>Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b900cafc13e77966de45d5820faff424"><gtr:id>b900cafc13e77966de45d5820faff424</gtr:id><gtr:otherNames>Irlam-Jones JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5a79b23c87a215.28214974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26759818-1F5B-4AB5-9109-F5A87223E805</gtr:id><gtr:title>Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0dc957f193284ffded40111bff3db5b"><gtr:id>c0dc957f193284ffded40111bff3db5b</gtr:id><gtr:otherNames>Ali HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>545a523d786769.46533269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>912393D9-0F21-4769-B1BF-47E5578AF015</gtr:id><gtr:title>Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa41d5a54770b22355ce31312ea5b54c"><gtr:id>fa41d5a54770b22355ce31312ea5b54c</gtr:id><gtr:otherNames>Mehta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>5899d4b5775907.54878405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D4128DB-6DD1-47A8-9EC0-4C028998E809</gtr:id><gtr:title>To branch or to expand?</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c66edd6884595cfce64f09ea6e346a"><gtr:id>b5c66edd6884595cfce64f09ea6e346a</gtr:id><gtr:otherNames>Bridges EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>57988dc2d61ca3.59674858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07DB3247-CCD8-476D-B1DD-C3AB414B332E</gtr:id><gtr:title>The CancerGrid experience: Metadata-based model-driven engineering for clinical trials</gtr:title><gtr:parentPublicationTitle>Science of Computer Programming</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77654537111c473e3f16947aa03d7fa6"><gtr:id>77654537111c473e3f16947aa03d7fa6</gtr:id><gtr:otherNames>Davies J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_55f98398376a0855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAF48DD2-93DF-48CD-8D3E-62C8D7173216</gtr:id><gtr:title>Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.</gtr:title><gtr:parentPublicationTitle>European journal of drug metabolism and pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7834f04b6fce9a2cf050fd961a3d5a0f"><gtr:id>7834f04b6fce9a2cf050fd961a3d5a0f</gtr:id><gtr:otherNames>Morotti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0378-7966</gtr:issn><gtr:outcomeId>5a79947f236691.96591515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68020D46-4C73-48E9-9D67-2D3ACCE54413</gtr:id><gtr:title>Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4611475df200eb5d57ddc81bbaf545a8"><gtr:id>4611475df200eb5d57ddc81bbaf545a8</gtr:id><gtr:otherNames>Milani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a79947edaf042.79694840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5D48B30-9399-46CD-BF01-FE950B394754</gtr:id><gtr:title>Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ace02fe3af0c8f78d6cac3f4e95faa0e"><gtr:id>ace02fe3af0c8f78d6cac3f4e95faa0e</gtr:id><gtr:otherNames>Haider S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>57988e666e9e82.22108684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31B31551-78AE-4D61-8AD2-DE0EC1C639FA</gtr:id><gtr:title>O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc266c2ce23de66188f609c5dbc5af06"><gtr:id>cc266c2ce23de66188f609c5dbc5af06</gtr:id><gtr:otherNames>Santos SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5899d4b61e6dd2.84867990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B05FB61D-43AE-475C-B146-C133A6E0005E</gtr:id><gtr:title>Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy.</gtr:title><gtr:parentPublicationTitle>Journal of molecular medicine (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae16783c3b60e4dc77f2f0a9d344c95e"><gtr:id>ae16783c3b60e4dc77f2f0a9d344c95e</gtr:id><gtr:otherNames>Zois CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0946-2716</gtr:issn><gtr:outcomeId>57988f489cbad6.63183289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>819F9879-A53E-413E-A412-18301623CBC1</gtr:id><gtr:title>In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b09de4809b43e4052ec951e509ca0d"><gtr:id>a4b09de4809b43e4052ec951e509ca0d</gtr:id><gtr:otherNames>Abu-Jamous B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>5a79947c07cc21.45820278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF66FA10-5F12-4757-B640-D14C8EEC9715</gtr:id><gtr:title>Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7042a769611b8c813962b922fcfeadb3"><gtr:id>7042a769611b8c813962b922fcfeadb3</gtr:id><gtr:otherNames>Dos Santos SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a79947cb5b789.79499307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56433F62-3C48-4316-88DE-52DAAF9640D5</gtr:id><gtr:title>A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a081b7ad9d3401878fdee97184bdc52c"><gtr:id>a081b7ad9d3401878fdee97184bdc52c</gtr:id><gtr:otherNames>Erdal E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn><gtr:outcomeId>5a79947d00e5f9.33538751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49BFAEA-555B-4712-89EB-0D0FE76660AC</gtr:id><gtr:title>Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79a76fc34ddf38e6701661654a0bed90"><gtr:id>79a76fc34ddf38e6701661654a0bed90</gtr:id><gtr:otherNames>Siriwardana PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>57988f483b2e09.64043097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B37140B5-7D3E-40E1-ACBB-D0F4A95144A1</gtr:id><gtr:title>Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0dc957f193284ffded40111bff3db5b"><gtr:id>c0dc957f193284ffded40111bff3db5b</gtr:id><gtr:otherNames>Ali HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>56d4580818ca65.11358751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>373D3BCF-8C5D-4F87-B7F3-37B901A737A7</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>57988fc0b795d0.74221533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA56FE08-B1D9-4E15-9C29-959505AAA089</gtr:id><gtr:title>The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e7ee67e340729528abed0e684f289bf"><gtr:id>6e7ee67e340729528abed0e684f289bf</gtr:id><gtr:otherNames>da Motta LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>57988dc34b77a1.53189552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBCC519F-E544-4DCC-87A1-88B2564F53EE</gtr:id><gtr:title>Imaging oligometastatic cancer before local treatment</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4519721e0ace2fd658917c3727d56ec6"><gtr:id>4519721e0ace2fd658917c3727d56ec6</gtr:id><gtr:otherNames>Franklin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5899d4b21335d6.41898338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68B0C8A9-A185-4DAB-A587-AED67347CD10</gtr:id><gtr:title>The Role of Oxygen in Avascular Tumor Growth.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1023adaf1860de116906925ed3043122"><gtr:id>1023adaf1860de116906925ed3043122</gtr:id><gtr:otherNames>Grimes DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>57988e6637c367.75634530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD2C54E7-C15A-4E73-BE7D-3DB835C4B84C</gtr:id><gtr:title>Data standards for minimum information collection for antibody therapy experiments.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68871cb7625ddc44ba80bdc9e4b1dcf"><gtr:id>f68871cb7625ddc44ba80bdc9e4b1dcf</gtr:id><gtr:otherNames>Yong M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>gV5ABLoarR8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>096FF9FA-03C4-48E2-BDCA-412892579151</gtr:id><gtr:title>Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acffa9974144c8b540091ff8e2812c32"><gtr:id>acffa9974144c8b540091ff8e2812c32</gtr:id><gtr:otherNames>Kleibeuker EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5899d4b4dac519.83831914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1477CB1B-9666-4E15-A711-90DAD71C9807</gtr:id><gtr:title>Model-driven engineering of information systems: 10 years and 1000 versions</gtr:title><gtr:parentPublicationTitle>Science of Computer Programming</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77654537111c473e3f16947aa03d7fa6"><gtr:id>77654537111c473e3f16947aa03d7fa6</gtr:id><gtr:otherNames>Davies J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_55faa1aa17906c40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2275E68C-4101-4908-9D05-5BB9D9455B74</gtr:id><gtr:title>Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc61126b8c619fe131d40ef773b4c9d1"><gtr:id>dc61126b8c619fe131d40ef773b4c9d1</gtr:id><gtr:otherNames>McIntyre A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>57988f47a961f6.49297129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D18A5BB-7416-46A4-A531-F72C26CC7387</gtr:id><gtr:title>From practice guidelines to clinical decision support: closing the loop.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd93323ca1f87347a200b0499bfb0deb"><gtr:id>bd93323ca1f87347a200b0499bfb0deb</gtr:id><gtr:otherNames>Fox J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>fZJ8Yise9Cu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0A8ACEC-EEE3-406A-B9E9-BCE937FCD12F</gtr:id><gtr:title>miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e78ac20abb96222c372563ff2effb20"><gtr:id>0e78ac20abb96222c372563ff2effb20</gtr:id><gtr:otherNames>Pajic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5a79947f9955b7.60956906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A829CEBC-E31E-4A54-AD45-52F8691A95C2</gtr:id><gtr:title>Single-cell heterogeneity in ductal carcinoma in situ of breast.</gtr:title><gtr:parentPublicationTitle>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/532f6a614aef104153b662e6a2e75913"><gtr:id>532f6a614aef104153b662e6a2e75913</gtr:id><gtr:otherNames>Gerdes MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-3952</gtr:issn><gtr:outcomeId>5a79947d37fe54.48979045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D997EE9-1AD3-4A1B-A023-5EF98F19DA8C</gtr:id><gtr:title>Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e569921980b35e43a50f38f0a33de75a"><gtr:id>e569921980b35e43a50f38f0a33de75a</gtr:id><gtr:otherNames>Lord S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>579890365d41d5.12521065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E5AE88D-C558-407E-A2CB-B44B946350BA</gtr:id><gtr:title>PathGrid: a service-orientated architecture for microscopy image analysis.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions. Series A, Mathematical, physical, and engineering sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab8dacc4e794da2aad032c05624d145b"><gtr:id>ab8dacc4e794da2aad032c05624d145b</gtr:id><gtr:otherNames>Walton NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1364-503X</gtr:issn><gtr:outcomeId>g4nKyoPREWw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41C8BF0B-2E5F-4F41-B720-AC3E3512C013</gtr:id><gtr:title>MEF2 transcription factors are key regulators of sprouting angiogenesis.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0b0e958ecf10565267471ba1313356d"><gtr:id>d0b0e958ecf10565267471ba1313356d</gtr:id><gtr:otherNames>Sacilotto N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn><gtr:outcomeId>5899d4b5e2de75.49624911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFAC33E0-D294-43BD-90B3-E23CD958092A</gtr:id><gtr:title>miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e26626ca5ffdccda7363f3b846f687"><gtr:id>16e26626ca5ffdccda7363f3b846f687</gtr:id><gtr:otherNames>Khoo CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a79947ea0c185.36680158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D16A7812-BED3-4DEB-A453-CA77BF4E4AFE</gtr:id><gtr:title>RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa30cc5042575584f40ab126f20f0b54"><gtr:id>fa30cc5042575584f40ab126f20f0b54</gtr:id><gtr:otherNames>Earwaker P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a7995a9a856e4.31063334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED74378A-1589-4B23-BFCE-18A8A3114284</gtr:id><gtr:title>A metadata-aware application for remote scoring and exchange of tissue microarray images.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95db6308e95b614474278b48f6c01f95"><gtr:id>95db6308e95b614474278b48f6c01f95</gtr:id><gtr:otherNames>Morris L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>pm_16254_24_23635078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>804B9B21-6619-4B84-BCDE-225A4F5AE39E</gtr:id><gtr:title>Antiangiogenic therapy in oncology: current status and future directions</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d75cc06ef727d51e77a523ce8de125d"><gtr:id>0d75cc06ef727d51e77a523ce8de125d</gtr:id><gtr:otherNames>Jayson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>57988e668ec751.62592059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6BE5EB8-3493-4E65-8BEA-085647E7265D</gtr:id><gtr:title>Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3defab565533adf3e3d831f535143bc1"><gtr:id>3defab565533adf3e3d831f535143bc1</gtr:id><gtr:otherNames>Gijsen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>57988dc36ac0b1.15753166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F986B4A-8C57-4DF5-977D-854F442CAD1A</gtr:id><gtr:title>Best use of experimental data in cancer informatics.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68871cb7625ddc44ba80bdc9e4b1dcf"><gtr:id>f68871cb7625ddc44ba80bdc9e4b1dcf</gtr:id><gtr:otherNames>Yong M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>ZJN1b8jnA4t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE70CC75-37A5-44FF-8F1F-684ED24C77DA</gtr:id><gtr:title>Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f7c754618080d84ce55600b152ecac2"><gtr:id>5f7c754618080d84ce55600b152ecac2</gtr:id><gtr:otherNames>Oon CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a79947f5f24e4.61427246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2775084-FD87-4B01-BF28-AE1A0A1F84AA</gtr:id><gtr:title>The Role of pH Regulation in Cancer Progression.</gtr:title><gtr:parentPublicationTitle>Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc61126b8c619fe131d40ef773b4c9d1"><gtr:id>dc61126b8c619fe131d40ef773b4c9d1</gtr:id><gtr:otherNames>McIntyre A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>978-3-319-42116-2</gtr:isbn><gtr:issn>0080-0015</gtr:issn><gtr:outcomeId>5899d4b53debe7.07474317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364C75F3-6903-4EDD-8A47-87662BD244B3</gtr:id><gtr:title>Paracrine effect of GTP cyclohydrolase and angiopoietin-1 interaction in stromal fibroblasts on tumor Tie2 activation and breast cancer growth.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>57988dc3042e95.36629293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15B487DD-FF92-49E2-8CE2-5306BB75F3FB</gtr:id><gtr:title>Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5837ec3272b5701677f511cad14d357"><gtr:id>c5837ec3272b5701677f511cad14d357</gtr:id><gtr:otherNames>Leek R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>978-3-319-26664-0</gtr:isbn><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>57988e66b0f622.33912347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D92870A9-65CA-497A-BAD0-D216789F4ECF</gtr:id><gtr:title>The tumour hypoxia induced non-coding transcriptome.</gtr:title><gtr:parentPublicationTitle>Molecular aspects of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eb82a334010a9abe7be02483e62e969"><gtr:id>7eb82a334010a9abe7be02483e62e969</gtr:id><gtr:otherNames>Choudhry H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0098-2997</gtr:issn><gtr:outcomeId>57988dc326c023.18633048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC2016B1-E898-4ABE-A025-23824956C293</gtr:id><gtr:title>Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c4df4241d0e1193d5aeffe9e19aab3d"><gtr:id>1c4df4241d0e1193d5aeffe9e19aab3d</gtr:id><gtr:otherNames>Yang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>5a7995aa9fd8d5.62994891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8DBBC7D-C656-4498-A197-7F01F9949DCA</gtr:id><gtr:title>Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0776ffe37447e28f8541970091e4aaaf"><gtr:id>0776ffe37447e28f8541970091e4aaaf</gtr:id><gtr:otherNames>Harjes U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5a79947d705a69.70830731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82FE875A-A678-4CAB-ADB3-5DC3CAF56DED</gtr:id><gtr:title>Why some tumours trigger neovascularisation and others don't: the story thus far.</gtr:title><gtr:parentPublicationTitle>Chinese journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b52cb53a525b4d4303665c68c7922f54"><gtr:id>b52cb53a525b4d4303665c68c7922f54</gtr:id><gtr:otherNames>Adighibe O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1944-446X</gtr:issn><gtr:outcomeId>57988dc2a7cfc0.02988571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AFF0F33-1914-4DDE-A109-73084713B82B</gtr:id><gtr:title>A metadata approach for clinical data management in translational genomics studies in breast cancer.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4300d720df18ed3d8ad28fcac4c5b029"><gtr:id>4300d720df18ed3d8ad28fcac4c5b029</gtr:id><gtr:otherNames>Papatheodorou I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>PRwCyeWXjJ1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC9356D5-9E87-4027-A5ED-E720B9DAD2B6</gtr:id><gtr:title>Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0764965160862a934b384dcabf0ed3f9"><gtr:id>0764965160862a934b384dcabf0ed3f9</gtr:id><gtr:otherNames>Radchenko V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-8051</gtr:issn><gtr:outcomeId>57988f4814ae36.40266949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F6EF7D4-9162-4844-B7DE-5B6608AF06F7</gtr:id><gtr:title>SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.</gtr:title><gtr:parentPublicationTitle>Investigational new drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fef59d988632d50bfcfa6b4d556481f"><gtr:id>1fef59d988632d50bfcfa6b4d556481f</gtr:id><gtr:otherNames>Koukourakis MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0167-6997</gtr:issn><gtr:outcomeId>5a7995aa589b10.44755089</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300648</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>